CTLA-4 (cytotoxic T-lymphocyte associated protein 4) is a protein on the surface of T cells that acts as a brake on the immune system. It prevents T cells from attacking too aggressively, which protects healthy tissue but can also shield cancer cells from immune destruction. Blocking this protein with drugs has become one of the most important breakthroughs in cancer treatment, earning James Allison the 2018 Nobel Prize in Physiology or Medicine.
How CTLA-4 Works as an Immune Brake
To understand CTLA-4, you need to know how T cells get activated. When a T cell encounters a threat, it needs two signals to fully switch on. The first comes from recognizing the threat itself. The second is a “go ahead” signal delivered when a protein called CD28 on the T cell connects with partner molecules (called B7) on nearby immune cells. That second signal is like a green light confirming the T cell should multiply and attack.
CTLA-4 works by competing directly with CD28 for those same B7 partner molecules. It binds to them with significantly higher affinity, meaning it latches on more tightly and effectively shoves CD28 out of the way. Once CTLA-4 grabs hold of B7, it accumulates at the contact point between cells and blocks the green light signal. Without that costimulatory boost, the T cell’s response is dampened or shut down entirely.
A small but critical sequence of amino acids in CTLA-4’s outer structure, called the MYPPPY motif, is what allows it to lock onto B7 molecules so effectively. This motif sits in the portion of the protein that extends outside the cell, and without it, CTLA-4 cannot perform its braking function.
When and Where T Cells Express CTLA-4
CTLA-4 isn’t always present on T cells. Its appearance is tightly controlled and depends on what type of T cell is involved and how recently it was activated. On most helper T cells, CTLA-4 shows up on the surface within about one to two hours of activation and peaks around four hours. What happens next depends on the cell type.
Naïve T cells, those that have never encountered their target before, ramp up CTLA-4 quickly but then dial it back down after about four hours. Memory T cells, which have been activated in the past, maintain high CTLA-4 levels for at least 48 hours. This difference matters because it means experienced immune cells keep a tighter leash on themselves for longer periods.
Regulatory T cells (a specialized subset that suppresses other immune cells) carry more CTLA-4 even at rest, roughly double the baseline level compared to non-regulatory T cells. Like memory cells, they sustain high CTLA-4 expression for at least 48 hours after activation. This persistent expression is central to their job of keeping the immune system in check.
CTLA-4 and Regulatory T Cells
Regulatory T cells are the immune system’s peacekeepers, and CTLA-4 is their primary tool. When regulatory T cells display CTLA-4 on their surface, the protein binds to B7 molecules on antigen-presenting cells (the cells responsible for alerting the immune system to threats). By occupying those B7 molecules, CTLA-4 prevents nearby naïve T cells from receiving their costimulatory green light. The result: the immune response is suppressed before it can escalate.
Research from the American Society of Hematology has shown that CTLA-4 is responsible for essentially all three hallmark functions of regulatory T cells: suppressing other immune cells, reducing their own signaling sensitivity, and entering a state of deliberate unresponsiveness called anergy. Mice whose regulatory T cells lack CTLA-4 develop fatal autoimmunity, which underscores just how essential this single protein is for preventing the immune system from turning on the body.
How CTLA-4 Differs From PD-1
CTLA-4 and PD-1 are both immune checkpoints, meaning they both restrain T cells. But they operate at different times and in different places. CTLA-4 acts early, during the initial activation of T cells, primarily in lymph nodes where immune responses begin. PD-1 acts later, dampening T cells that have already been activated and traveled out to tissues throughout the body.
The ligands they bind to also have different distribution patterns. The B7 molecules that CTLA-4 targets are found mainly on professional antigen-presenting cells in lymphoid tissue. PD-1’s partner molecules are expressed much more broadly, including on tumor cells themselves and in a wide range of organs. This is why CTLA-4 is often described as a checkpoint that governs whether an immune response starts at all, while PD-1 governs whether an ongoing response continues in the tissues where it’s needed.
These complementary roles explain why combination therapies targeting both checkpoints simultaneously can be more effective than blocking either one alone.
CTLA-4 Blockade in Cancer Treatment
In 1996, James Allison published a landmark paper showing that blocking CTLA-4 with an antibody unleashed T cells to destroy tumors in mice. That discovery eventually led to ipilimumab (brand name Yervoy), the first and still only FDA-approved drug that specifically blocks CTLA-4. Allison shared the 2018 Nobel Prize in Physiology or Medicine with Tasuku Honjo, who made parallel discoveries about PD-1.
Ipilimumab is approved for several cancers. It was first licensed for advanced melanoma (stage 3 or 4) and is also used as a post-surgery treatment for earlier-stage melanoma after complete removal. In combination with nivolumab, a PD-1 blocker, it is approved for intermediate or poor-risk advanced kidney cancer, and for certain colorectal cancers that have specific genetic features (microsatellite instability-high or mismatch repair deficient) and have stopped responding to standard chemotherapy.
Removing the CTLA-4 brake is powerful but comes with a cost. Because you’re unleashing the immune system broadly, it can attack healthy tissues. In the pivotal CheckMate 067 trial, 26% of patients receiving ipilimumab alone at standard dosing experienced severe immune-related side effects. When ipilimumab was combined with nivolumab, that figure rose to 33%. These reactions can affect the gut, liver, skin, hormone-producing glands, and other organs. Most are manageable with prompt treatment, but they require close monitoring.
What Happens When CTLA-4 Is Missing
Some people are born with only one functional copy of the CTLA-4 gene, a condition called CTLA-4 haploinsufficiency. Without enough CTLA-4 to properly restrain immune cells, these individuals develop a pattern of immune overactivation that can affect multiple organs.
The most common symptom is chronic diarrhea or other intestinal disease caused by immune cells infiltrating the gut lining. Enlarged lymph nodes, liver, and spleen are also typical. Many people with this deficiency experience autoimmune problems affecting the blood, thyroid, skin, or joints, along with frequent respiratory infections. The condition also carries a modestly increased risk of lymphoma. Diagnosis involves a combination of clinical symptoms, blood work, and genetic testing to confirm the mutation, according to the National Institute of Allergy and Infectious Diseases.
CTLA-4 deficiency offers a natural demonstration of why this protein matters. The same immune hyperactivation that makes blocking CTLA-4 effective against cancer is what causes disease when the protein is missing from birth. It’s essentially the flip side of cancer immunotherapy: too little CTLA-4 activity causes autoimmunity, while too much shields tumors from destruction.